Novartis will collect new data will help it take on Pfizer. It probably won't

A pretty impressive result from ASCO is also published in the New England Journal of Medicine: Kisqali, a cancer drug from Novartis (NVS), dramatically extended survival in younger women who developed the most common form of breast cancer.

In women with hormone receptor positive / HER2 negative breast cancer who were premenopausal, adding Kisqali to hormone-blocking therapy resulted in a reduction of 29% in the risk of death. After three and a half years, translates into 70% of the women who got the combination being alive, compared to 42% of those who got the standard therapy. That is a dramatic improvement in a disease where it is often hard to prove a survival benefit.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


Source link

Back to top button